The findings demonstrated the downregulation of pro-inflammatory markers TNF-α, IL-1ß, IL-6, NF-KB, MMP3, COX-I, COX-II and upregulation of anti-inflammatory markers IL-4 following CED treatment. The gene discussed is NFKB1; the disease is cranioectodermal dysplasia.